| dc.contributor.author | Di Giambenedetto, Simona, et al. | |
| dc.date.accessioned | 2020-04-30T01:08:28Z | |
| dc.date.available | 2020-04-30T01:08:28Z | |
| dc.date.issued | 2020-04-16 | |
| dc.identifier.uri | https://doi.org/10.1002/jmv.25897 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/1247 | |
| dc.description.abstract | The spread of the novel‐Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti‐human inteleukine‐6 receptor antibody tocilizumab seems a promising strategy for these patients. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | Infectious Diseases | en_US |
| dc.title | Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2 Infection | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Candidate therapeutics RD | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Journal of Medical Virology | en_US |
